Next Article in Journal
The Synthesis of Various 2-Imino-2H-chromene-3-carbonitrile Derivatives
Previous Article in Journal
Breast Cancer Screening Using Artificial Intelligence Techniques: Enhancing Biochemical Insights and Diagnostic Accuracy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Proceeding Paper

Effects of N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides on Intestinal Microbial Communities †

1
Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
2
Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Palackeho 1946/1, 612 00 Brno, Czech Republic
3
Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovicova 6, 842 15 Bratislava, Slovakia
4
Department of Chemical Biology, Faculty of Science, Palacky University Olomouc, Slechtitelu 27, 783 71 Olomouc, Czech Republic
*
Authors to whom correspondence should be addressed.
Presented at the 27th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-27), 15–30 November 2023; Available online: https://ecsoc-27.sciforum.net/.
Chem. Proc. 2023, 14(1), 45; https://doi.org/10.3390/ecsoc-27-16142
Published: 15 November 2023

Abstract

:
The phylum Proteobacteria, more precisely, the family Enterobacteriaceae, has been shown to be a major cause of inflammation in the human microbiome. Their standard level in the human intestine is usually kept below 1% in a healthy person, and their overgrowth above this number leads to intestinal inflammation, which can cause the development of inflammatory bowel diseases, most often, Crohn’s disease or ulcerative colitis. The minimum inhibitory concentrations (MICs) of a series of eighteen recently synthesized N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides were determined against two representatives of the Enterobacteriaceae family–Escherichia coli CCM 3954 and Salmonella typhimurium LT 2-18. Although the tested compounds are cyclic analogues of salicylanilides known to have strong antimicrobial properties, the found MICs ranged between 50 µM and 1000 µM. However, it can be concluded that S. typhimurium was generally more sensitive to the tested antimicrobial agents than E. coli. N-[2-(But-2-yloxy)phenyl]-1-hydroxynaphthalene-2-carboxamide was the most active agent among the investigated compounds with an MIC of 100 µM against E. coli and an MIC of 50 µM against S. typhimurium.

1. Introduction

Enterobacteriaceae is a large family of Gram-negative, facultatively anaerobic rods, most of which live in the digestive tract as a natural part of the intestinal microflora. Most are non-pathogenic, but some are conditionally pathogenic and some species are dangerous agents of serious and fatal diseases (e.g., Salmonella, Shigella, Yersinia pestis, some strains of Escherichia coli) [1].
The presence of pathogenic enterobacteria in the gastrointestinal tract can greatly alter the diversity and abundance of beneficial bacteria. For example, it is well-known that adherent invasive strains of E. coli colonize the intestinal mucosa and prevent the proper function of intestinal immune cells, causing major damage to the epithelial barrier, which plays an important role in regulating interactions between the luminal contents of the gut and the rest of the body. Thus, pathogenic enterobacteria tend to be highly inflammatory and play a significant role in the development of inflammatory bowel diseases–chronic, immune-related diseases of the gastrointestinal tract with multifactorial and unclear pathogenesis [2,3,4,5].
Salicylanilides represented by, e.g., niclosamide [6,7], are simple, small and relatively old molecules, which, however, still surprise with a wide range of biological activities and the ability to influence various cell structures [8,9,10,11,12]. Hydroxynaphthalenecarboxanilides can be considered as cyclic analogues of salicylanilides and have also been described mainly for their anti-invasive activity against both cancer lines and Gram-positive bacteria and mycobacteria [13,14,15,16,17,18].
Following the previous studies, a series of N-(alkoxyphenyl)-1-hydroxynaphthalene- 2-carboxamides was tested for their ability to inhibit the growth of Gram-negative intestinal bacteria from the Enterobacteriaceae family represented by Escherichia coli and Salmonella typhimurium species, with the aim that if any of tested compounds achieves antimicrobial activity against the test species at a reasonable minimum inhibitory concentration (MIC), its possible potential for use in inflammatory bowel disease therapy will be explored.

2. Materials and Methods

2.1. Synthesis

All the discussed N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides 118 were synthesized using microwave-assisted synthesis, as described recently by Gonec et al. [13,14].

2.2. In Vitro Antibacterial Susceptibility Testing

In vitro antibacterial activity of the synthesized compounds was evaluated against representatives of two strains of intestinal bacteria (Escherichia coli CCM 3954 and Salmonella typhimurium LT 2-18), which are included into the Enterobacteriaceae family. The bacterial cultures were cultivated at 37 °C in standard liquid medium (nutrient broth, code: CM0001). A 1% solution of bacteria and nutrient broth was prepared before each experiment and subsequently incubated for approx. 24 h. After this incubation, the bacterial culture was diluted 10 more times (with pure nutrient broth) in order to achieve a suitable concentration that will provide an easily discernible growth curve. The optimal pH for the growth of both E. coli CCM 3954 and S. typhimurium LT 2-18 is in the range of 6.5 to 7.5. The pH of the nutrient broth used in each experiment was adjusted to fall between these values using hydrochloric acid to reduce the pH and sodium hydroxide to increase it. Each of the tested agents was dissolved using dimethyl sulfoxide [19]. Due to the difference in mass and molecular weight, the above calculation was repeated for each compound and for each concentration tested.
The equipment used for the majority of the experiment was a Bioscreen C (Bioscreen, Helsinki, Finland), an automated machine suitable for various microbiological experiments [20]. It monitors the growth of microorganisms by measuring the turbidity of liquid growth medium kinetically using the principle of vertical photometry, and then recording it as optical density measurements. A light beam penetrates though the bottom of the plate well, through the sample suspension, and to the detector. The growth of the bacteria in a Bioscreen C becomes visible twice faster than in a Petri dish, and four times faster if the shaking feature is used (it was not used in this experiment). A controlled environment is maintained by software throughout the whole process [20]. The incubation temperature, time, measuring intervals and wavelength can all be manually set. The wavelength used in this experiment was 600 nm, measuring intervals were set at 1 h. A total of 48 measurements were collected over the course of 48 h, 37 °C temperature was maintained during this time. The maximum capacity of the machine is two honeycomb plates, which altogether contain 200 wells; up to 31 concentrations were measured each time (9 wells had to be reserved for controls: three for negative control, three for positive control for S. typhimurium LT 2-18, and three for positive control for E. coli CCM 3954).
The second stage of the experiment used Bioscreen C and successfully generated a growth curve and determined a minimum inhibitory concentration for most of the antimicrobial agents by measuring their optical density (O.D.) at 1 h intervals over the course of 48 h. For this experiment, the incubation and subsequent dilution of the bacterial cultures before each experiment followed the same steps as the process. A honeycomb plate with 100 wells was used for the Bioscreen C, each well had a capacity of 250 µL. Six wells were used in total for each concentration tested, three of which contained bacteria and nutrient broth solution + compound, and three more wells after them containing only plain nutrient broth and compound (no bacteria). This was conducted to eliminate the possibility of the growth curve being influenced by any colour changes of the compounds, as most of them were not colourless. Three of each was the amount chosen as 3 is the minimum amount needed to obtain a statistically valid result. The values received from the 3 wells without compound were averaged, and then subtracted from the values received from the 3 wells with compound (also averaged beforehand). The final value obtained formed 1 of the 48 points in each growth curve. Pure nutrient broth was used as a negative control, and nutrient broth + bacterial solution was used as a positive control. Each experiment had two positive controls–one for S. typhimurium LT 2-18, and one for E. coli CCM 3954, therefore 9 wells were reserved for controls every time.

3. Results and Discussion

All eighteen studied compounds were prepared by condensation of 1-hydroxynaphthalene-2-carboxylic acid with appropriately alkoxy-substituted anilines in dry chlorobenzene using phosphorous chloride and microwave radiation in a microwave reactor as shown in Scheme 1. Alkoxy-substituted anilines occur either commercially and were purchased (anisidines) or were prepared from aminophenols and alkyl bromide according to De Marco et al. [21]. All the discussed compounds were described in detail in Gonec et al. [13,14] and are listed in Table 1.
All compounds were evaluated for their ability to inhibit in vitro growth of Gram-negative bacteria Escherichia coli CCM 3954 and Salmonella typhimurium LT 2-18, members of the Enterobacteriacea family. The efficacy of the individual compounds was expressed as minimal inhibitory concentrations (MICs), i.e., 90% or more (IC90) reduction of bacterial growth compared to the control [22]. The results are shown in Table 1, and, according to the MIC values, it can be seen that the compounds showed insignificant activity against the mentioned types of bacteria, which ranged from 50 to 1000 µM.
N-[2-(But-2-yloxy)phenyl]-1-hydroxynaphthalene-2-carboxamide (16) was the most effective against both tested bacterial strains with an MIC of 100 µM against E. coli and an MIC of 50 µM against S. typhimurium. 1-Hydroxy-N-(3-methoxyphenyl)naphthalene- 2-carboxamide (3) and N-[4-(but-2-yloxy)phenyl]-1-hydroxynaphthalene-2-carboxamide (18) were other derivatives, which showed some effect in inhibiting the growth of both bacteria (all MICs = 200 µM). As evident from the results mentioned in Table 1, the compounds were slightly more active against S. typhimurium. Unsubstituted 1-hydroxy-N-phenylnaphthalene-2-carboxamide (1) was completely inactive (MICs >1000 µM).

4. Conclusions

Thus, although hydroxynaphthalenecarboxamides have shown strong antibacterial and antimycobacterial effects even when substituted with methyl and methoxy groups, 1-hydroxynaphthalene-2-carboxamides substituted in this way with longer alkoxy tails are not suitable as agents for the inhibition of intestinal microorganisms potentially involved in the development and progression of inflammatory bowel diseases.

Author Contributions

Conceptualization, J.J.; methodology, T.G. and I.K.; investigation, V.N., T.G. and I.K.; writing—original draft preparation, T.G., I.K. and J.J.; funding acquisition, T.G., I.K. and J.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Grant Agency of Masaryk University (MUNI/A/1280/2022 and MUNI/A/1210/2022), by VEGA 1/0116/22 and by APVV-22-0133.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Dahal, P. Enterobacteriaceae—Definition, Characteristics, Identification. Microbe Notes. 2023. Available online: https://microbenotes.com/enterobacteriaceae (accessed on 22 September 2023).
  2. Axelrad, J.E.; Cadwell, K.H.; Colombel, J.F.; Shah, S.C. The role of gastrointestinal pathogens in inflammatory bowel disease: A systematic review. Therap. Adv. Gastroenterol. 2021, 14, 17562848211004493. [Google Scholar] [CrossRef] [PubMed]
  3. Zhang, L.; Liu, F.; Xue, J.; Lee, S.A.; Liu, L.; Riordan, S.M. Bacterial species associated with human inflammatory bowel disease and their pathogenic mechanisms. Front. Microbiol. 2022, 13, 801892. [Google Scholar] [CrossRef] [PubMed]
  4. Nishida, A.; Inoue, R.; Inatomi, O.; Bamba, S.; Naito, Y.; Andoh, A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 2018, 11, 1–10. [Google Scholar] [CrossRef] [PubMed]
  5. Liu, S.; Zhao, W.; Lan, P.; Mou, X. The microbiome in inflammatory bowel diseases: From pathogenesis to therapy. Protein Cell. 2021, 12, 331–345. [Google Scholar] [CrossRef] [PubMed]
  6. Niclosamide–DrugBank. Available online: https://go.drugbank.com/drugs/DB06803 (accessed on 22 September 2023).
  7. Jiang, H.; Li, A.M.; Ye, J. The magic bullet: Niclosamide. Front. Oncol. 2022, 12, 1004978. [Google Scholar] [CrossRef] [PubMed]
  8. Zadrazilova, I.; Pospisilova, S.; Masarikova, M.; Imramovsky, A.; Ferriz, J.M.; Vinsova, J.; Cizek, A.; Jampilek, J. Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). Eur. J. Pharm. Sci. 2015, 77, 197–207. [Google Scholar] [CrossRef] [PubMed]
  9. Copp, J.N.; Pletzer, D.; Brown, A.S.; Van der Heijden, J.; Miton, C.M.; Edgar, R.J.; Rich, M.H.; Little, R.F.; Williams, E.M.; Hancock, R.E.W.; et al. Mechanistic understanding enables the rational design of salicylanilide combination therapies for Gram-negative infections. mBio 2020, 11, e02068-20. [Google Scholar] [CrossRef]
  10. Kushkevych, I.; Kollar, P.; Ferreira, A.L.; Palma, D.; Duarte, A.; Lopes, M.M.; Bartos, M.; Pauk, K.; Imramovsky, A.; Jampilek, J. Antimicrobial effect of salicylamide derivatives against intestinal sulfate-reducing bacteria. J. Appl. Biomed. 2016, 14, 125–130. [Google Scholar] [CrossRef]
  11. Kauerova, T.; Perez-Perez, M.J.; Kollar, P. Salicylanilides and their anticancer properties. Int. J. Mol. Sci. 2023, 24, 1728. [Google Scholar] [CrossRef]
  12. Pindjakova, D.; Pilarova, E.; Pauk, K.; Michnova, H.; Hosek, J.; Magar, P.; Cizek, A.; Imramovsky, A.; Jampilek, J. Study of biological activities and ADMET-related properties of salicylanilide-based peptidomimetics. Int. J. Mol. Sci. 2022, 23, 11648. [Google Scholar] [CrossRef]
  13. Gonec, T.; Kos, J.; Zadrazilova, I.; Pesko, M.; Keltosova, S.; Tengler, J.; Bobal, P.; Kollar, P.; Cizek, A.; Kralova, K.; et al. Antimycobacterial and herbicidal activity of ring-substituted 1-hydroxynaphthalene-2-carboxanilides. Bioorg. Med. Chem. 2013, 21, 6531–6541. [Google Scholar] [CrossRef] [PubMed]
  14. Gonec, T.; Pospisilova, S.; Kauerova, T.; Kos, J.; Dohanosova, J.; Oravec, M.; Kollar, P.; Coffey, A.; Liptaj, T.; Cizek, A.; et al. N-Alkoxyphenylhydroxynaphthalenecarboxamides and their antimycobacterial activity. Molecules 2016, 21, 1068. [Google Scholar] [CrossRef] [PubMed]
  15. Michnova, H.; Pospisilova, S.; Gonec, T.; Kapustikova, I.; Kollar, P.; Kozik, V.; Musiol, R.; Jendrzejewska, I.; Vanco, J.; Travnicek, Z.; et al. Bioactivity of methoxylated and methylated 1-hydroxynaphthalene-2-carboxanilides: Comparative molecular surface analysis. Molecules 2019, 24, 2991. [Google Scholar] [CrossRef] [PubMed]
  16. Gonec, T.; Pindjakova, D.; Vrablova, L.; Strharsky, T.; Michnova, H.; Kauerova, T.; Kollar, P.; Oravec, M.; Jendrzejewska, I.; Cizek, A.; et al. Antistaphylococcal activities and ADME-related properties of chlorinated arylcarbamoylnaphthalenylcarbamates. Pharmaceuticals 2022, 15, 715. [Google Scholar] [CrossRef] [PubMed]
  17. Spaczynska, E.; Mrozek-Wilczkiewicz, A.; Malarz, K.; Kos, J.; Gonec, T.; Oravec, M.; Gawecki, R.; Bak, A.; Dohanosova, J.; Kapustikova, I.; et al. Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action. Sci. Rep. 2019, 9, 6387. [Google Scholar] [CrossRef] [PubMed]
  18. Campos, L.E.; Garibotto, F.; Angelina, E.; Kos, J.; Gonec, T.; Marvanova, P.; Vettorazzi, M.; Oravec, M.; Jendrzejewska, I.; Jampilek, J.; et al. Hydroxynaphthalenecarboxamides and substituted piperazinylpropandiols, two new series of BRAF inhibitors. A theoretical and experimental study. Bioorg. Chem. 2020, 103, 104145. [Google Scholar] [CrossRef] [PubMed]
  19. Capriotti, K.; Capriotti, J.A. Dimethyl sulfoxide. J. Clin. Aesthet. Dermatol. 2012, 5, 24–26. [Google Scholar] [PubMed]
  20. Bioscreen C–Mbio.ncsu.edu, User’s Manual. Yumpu.Com. Available online: https://www.yumpu.com/en/document/read/48827581/bioscreen-c-mbioncsuedu (accessed on 26 September 2023).
  21. De Marco, A.; De Candia, M.; Carotti, A.; Cellamare, S.; De Candia, E.; Altomare, C. Lipophilicity-related inhibition of blood platelet aggregation by nipecotic acid anilides. Eur. J. Pharm. Sci. 2004, 22, 153–164. [Google Scholar] [CrossRef] [PubMed]
  22. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed.; M07; NCCLS: Wayne, PA, USA, 2018. [Google Scholar]
Scheme 1. Synthesis of N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides. Reagents and conditions: (a) R-Br, NaH, acetonitrile, room temperature, 24 h [21]; (b) PCl3, chlorobenzene, MW, 15 min. [13,14].
Scheme 1. Synthesis of N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides. Reagents and conditions: (a) R-Br, NaH, acetonitrile, room temperature, 24 h [21]; (b) PCl3, chlorobenzene, MW, 15 min. [13,14].
Chemproc 14 00045 sch001
Table 1. Structures of discussed ring-substituted N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carbox- amides 118 and in vitro activity (MIC) against Escherichia coli CCM 3954 and Salmonella typhimurium LT 2-18.
Table 1. Structures of discussed ring-substituted N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carbox- amides 118 and in vitro activity (MIC) against Escherichia coli CCM 3954 and Salmonella typhimurium LT 2-18.
Chemproc 14 00045 i001
No.RMIC (µM)
E. coliS. typhimurium
1H>1000>1000
22-OCH39001000
33-OCH3200200
42-OC2H5300300
53-OC2H5400200
64-OC2H5600600
72-OC3H7500200
83-OC3H7300200
94-OC3H7500200
102-OC4H9400200
113-OC4H9300200
124-OC4H9400300
132-OCH(CH3)2400200
143-OCH(CH3)2300200
154-OCH(CH3)2400300
162-OCH(CH3)CH2CH310050
173-OCH(CH3)CH2CH3400300
184-OCH(CH3)CH2CH3200200
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nikolaeva, V.; Gonec, T.; Kushkevych, I.; Jampilek, J. Effects of N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides on Intestinal Microbial Communities. Chem. Proc. 2023, 14, 45. https://doi.org/10.3390/ecsoc-27-16142

AMA Style

Nikolaeva V, Gonec T, Kushkevych I, Jampilek J. Effects of N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides on Intestinal Microbial Communities. Chemistry Proceedings. 2023; 14(1):45. https://doi.org/10.3390/ecsoc-27-16142

Chicago/Turabian Style

Nikolaeva, Vanina, Tomas Gonec, Ivan Kushkevych, and Josef Jampilek. 2023. "Effects of N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides on Intestinal Microbial Communities" Chemistry Proceedings 14, no. 1: 45. https://doi.org/10.3390/ecsoc-27-16142

APA Style

Nikolaeva, V., Gonec, T., Kushkevych, I., & Jampilek, J. (2023). Effects of N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides on Intestinal Microbial Communities. Chemistry Proceedings, 14(1), 45. https://doi.org/10.3390/ecsoc-27-16142

Article Metrics

Back to TopTop